{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Microsatellite+Instability-High+Cancer&page=2", "query": { "condition": "Microsatellite Instability-High Cancer", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Microsatellite+Instability-High+Cancer&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-21T23:29:14.089Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03228667", "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "Small Cell Lung Cancer", "Urothelial Carcinoma", "Head and Neck Squamous Cell Carcinoma", "Merkel Cell Carcinoma", "Melanoma", "Renal Cell Carcinoma", "Gastric Cancer", "Cervical Cancer", "Hepatocellular Carcinoma", "Microsatellite Instability", "Mismatch Repair Deficiency", "Colorectal Cancer" ], "interventions": [ { "name": "N-803 + Pembrolizumab", "type": "DRUG" }, { "name": "N-803 + Nivolumab", "type": "DRUG" }, { "name": "N-803 + Atezolizumab", "type": "DRUG" }, { "name": "N-803 + Avelumab", "type": "DRUG" }, { "name": "N-803 + Durvalumab", "type": "DRUG" }, { "name": "N-803 + Pembrolizumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Nivolumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Atezolizumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Avelumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Durvalumab + PD-L1 t-haNK", "type": "DRUG" }, { "name": "N-803 + Docetaxel + Pembrolizumab", "type": "DRUG" }, { "name": "N-803 + Docetaxel + Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-12-11", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-05-21T23:29:14.089Z", "location_count": 35, "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "El Segundo", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03228667" }, { "nct_id": "NCT02060188", "title": "A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Microsatellite Unstable Colorectal Cancer", "Microsatellite Stable Colorectal Cancer", "Mismatch Repair Proficient Colorectal Cancer", "Mismatch Repair Deficient Colorectal Cancer" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "BMS-986016", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 385, "start_date": "2014-03-12", "completion_date": "2024-10-22", "has_results": true, "last_update_posted_date": "2025-11-06", "last_synced_at": "2026-05-21T23:29:14.089Z", "location_count": 14, "location_summary": "Gilbert, Arizona • Los Angeles, California • San Francisco, California + 10 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02060188" }, { "nct_id": "NCT05199272", "title": "A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Clear Cell Renal Cell Carcinoma", "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Carcinoma", "Neuroendocrine Tumors", "MSI-H Cancer", "Cancer With A High Tumor Mutational Burden", "Extensive-stage Small-cell Lung Cancer" ], "interventions": [ { "name": "23ME-00610", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "23andMe, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 141, "start_date": "2021-12-29", "completion_date": "2025-03", "has_results": false, "last_update_posted_date": "2024-11-15", "last_synced_at": "2026-05-21T23:29:14.089Z", "location_count": 10, "location_summary": "Palo Alto, California • Atlanta, Georgia • Detroit, Michigan + 7 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Lake Success", "state": "New York" }, { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05199272" }, { "nct_id": "NCT07140679", "title": "Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Localized Colon Carcinoma", "Stage IIB Colon Cancer AJCC v8", "Stage IIC Colon Cancer AJCC v8", "Stage III Colon Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Colonoscopy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Toripalimab", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2025-09-19", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-05-21T23:29:14.089Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Johns Creek, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Johns Creek", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07140679" }, { "nct_id": "NCT06034860", "title": "Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Hepatocellular Carcinoma", "Melanoma", "Renal Cell Carcinoma", "Microsatellite Instability High", "Mismatch Repair Deficiency", "Mesothelioma", "Esophageal Squamous Cell Carcinoma", "Squamous Cell Carcinoma of Head and Neck", "Urothelial Carcinoma", "Cervical Cancer" ], "interventions": [ { "name": "MT-8421", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Molecular Templates, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2023-11-01", "completion_date": "2024-10-31", "has_results": false, "last_update_posted_date": "2024-11-01", "last_synced_at": "2026-05-21T23:29:14.089Z", "location_count": 5, "location_summary": "Los Angeles, California • Lafayette, Indiana • St Louis, Missouri + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06034860" }, { "nct_id": "NCT05200559", "title": "T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Epithelial Ovarian Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "E7777", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexander B Olawaiye, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 70, "start_date": "2022-09-30", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2024-12-05", "last_synced_at": "2026-05-21T23:29:14.089Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05200559" }, { "nct_id": "NCT04001101", "title": "Anti-PD-1 +/- RT for MSI-H Solid Tumors", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Microsatellite Instability High", "Mismatch Repair Deficiency", "Colorectal Cancer" ], "interventions": [ { "name": "RT and Anti-PD-1", "type": "COMBINATION_PRODUCT" }, { "name": "Anti-PD-1", "type": "DRUG" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 0, "start_date": "2019-10-10", "completion_date": "2021-11-17", "has_results": false, "last_update_posted_date": "2021-11-30", "last_synced_at": "2026-05-21T23:29:14.089Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04001101" }, { "nct_id": "NCT05909995", "title": "Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Hepatocellular Carcinoma (HCC)", "Renal Cell Carcinoma (RCC)", "Microsatellite Instability - High (MSI-H)", "Mismatch Repair Deficient (dMMR)", "Colorectal Carcinoma (CRC)" ], "interventions": [ { "name": "INCB 99280 with Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2023-08-29", "completion_date": "2024-11-11", "has_results": false, "last_update_posted_date": "2025-02-18", "last_synced_at": "2026-05-21T23:29:14.089Z", "location_count": 5, "location_summary": "Los Angeles, California • Orange, California • San Diego, California + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05909995" }, { "nct_id": "NCT03775850", "title": "A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer Metastatic", "Triple Negative Breast Cancer", "Non Small Cell Lung Cancer", "Bladder Cancer", "GastroEsophageal Cancer", "Renal Cell Carcinoma", "MSI-H" ], "interventions": [ { "name": "EDP1503", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Evelo Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2018-12-19", "completion_date": "2021-10-31", "has_results": false, "last_update_posted_date": "2023-03-24", "last_synced_at": "2026-05-21T23:29:14.089Z", "location_count": 5, "location_summary": "Rogers, Arkansas • Sarasota, Florida • Oklahoma City, Oklahoma + 2 more", "locations": [ { "city": "Rogers", "state": "Arkansas" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Chattanooga", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03775850" }, { "nct_id": "NCT05723562", "title": "A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Rectal" ], "interventions": [ { "name": "Dostarlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 154, "start_date": "2023-04-03", "completion_date": "2029-10-11", "has_results": false, "last_update_posted_date": "2026-01-08", "last_synced_at": "2026-05-21T23:29:14.089Z", "location_count": 7, "location_summary": "Los Angeles, California • Albuquerque, New Mexico • New York, New York + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05723562" } ] }